Episodes

  • The Lp(a) Letdown and Tumors After Gene Therapy

    The Lp(a) Letdown and Tumors After Gene Therapy
    Nov 13 2026
    Friday, November 13, 2026 In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) & Eva Johnson cover two large heart drug trials that lowered markers but not events. They break down Lp(a)HORIZON, which tested pelacarsen, and ZEUS, which tested ziltivekimab. They explain why moving a risk marker is not the same as changing outcomes. Plus: they also discuss an FDA investigation into tumors after the SMA gene therapy Zolgensma, what monitoring may mean for practice, an NFL star's scary neck injury, and more. Coverage Timeline: (00:00) This Week’s Headlines (01:44) Pelacarsen: Big Drop, No Benefit (03:03) ZEUS Falls Flat (05:24) Gene Therapy’s Tumor Risk (08:05) Plasma Hack, AI Prior Auth & Statin Nudges (09:45) Jack Campbell’s Recovery Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    13 mins
  • Healthcare at the Midterms, a CVS Divorce, and the NFL’s CTE Problem

    Healthcare at the Midterms, a CVS Divorce, and the NFL’s CTE Problem
    Nov 6 2026
    Friday, November 6, 2026 In today's episode, Dr. Will Flanary (@drglaucomflecken) & Adam Rose (@adjoro) cover a new JAMA Network Open estimate that 74.5 percent of deceased former NFL players had CTE after correcting for brain bank selection bias. They break down how researchers modeled donation bias and why the finding still cannot estimate risk for living players. They also dig into how the NFL and players association responded and what it means for counseling patients on head injury risk. Plus: they also discuss the 2026 midterm election results in which several doctors won their races, CVS splitting up, a major dialysis trial that stopped early, and more. Coverage Timeline: (00:00) Intro (01:27) CTE Among Former NFL Players (05:30) French ICU Dialysis Trial (09:09) 2026 Midterm Result (13:05) CVS Health Split (14:30) Phone Location Data Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    17 mins
  • Biting Back at Ticks and Christina Applegate’s Mystery Illness

    Biting Back at Ticks and Christina Applegate’s Mystery Illness
    Oct 30 2026
    Friday, October 30, 2026 In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) & Eva Johnson cover full phase three results for a Lyme disease vaccine, and Psychiatry Boot Camp host Dr. Mark Mullen pays a visit. They break down a new once monthly olanzapine shot for schizophrenia. Plus: a dementia study built on a 1972 British school reform, why Christina Applegate says her MS diagnosis was wrong, and GLP-1 drugs may affect drinking habits in the UK. Thank you to guest anchor Dr. Mark Mullen! Check out his podcast Psychiatry Boot Camp, available every other Monday on YouTube and all your favorite podcast apps. To learn more, visit psychiatrybootcamp.com Coverage Timeline: (0:00) Intro (1:26) Lyme Disease Vaccine (3:31) Vaccine Safety & History (5:07) Schizophrenia Treatment (8:26) School & Dementia Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    15 mins
  • Hospital Detox Shakeup and NFL Star Sidelined

    Hospital Detox Shakeup and NFL Star Sidelined
    Oct 23 2026
    Friday, October 23, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a phase three trial of nicotinamide riboside in early Parkinson disease. Over 52 weeks, the supplement boosted NAD metabolism but showed no clinical benefit, raising questions for NAD boosting strategies. They also walk through a large hospital comparison of phenobarbital and diazepam for alcohol withdrawal, with similar stays and ventilation rates and fewer self directed discharges on phenobarbital, and why diazepam protocols may stay the course pending randomized trials. Plus: they also discuss national measles trends, FDA warning letters to Amazon and Walmart, and more. Coverage Timeline: (00:00) Intro (01:05) NR Supplement Trial for Parkinson's (03:01) NAD Supplements & Influencer Hype (04:49) Phenobarbital vs. Diazepam (07:30) Measles Surge in US (08:27) New Sunscreen Ingredient BEMT (09:01) Blood Clots Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    14 mins
  • Schizophrenia Gets an App and Your Dog Is Losing Sleep

    Schizophrenia Gets an App and Your Dog Is Losing Sleep
    Oct 16 2026
    Friday, October 16, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Eva Johnson cover the FDA clearance of Motivista as the first prescription app for negative symptoms of schizophrenia. They break down the 16 week CONVOKE trial and what a 2.6 point edge over a control app means for stable patients on antipsychotics. They also review new ACP guidance placing menopausal hormone therapy first for hot flashes and night sweats, with second and third line options. Plus: they discuss early feasibility data on a medical AI chatbot for pre visit histories, new federal recommendations on concentrated kratom products, and more. Coverage Timeline: (00:00) Intro (01:08) Schizophrenia App Cleared (03:50) Hot Flashes Guidance (04:47) Dogs & Sleep Study (06:51) AI In Urgent Care (08:37) Awards & Dahlias Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    14 mins
  • GLP-1 Shakeups and Airline Emergency Kit Upgrades

    GLP-1 Shakeups and Airline Emergency Kit Upgrades
    Oct 9 2026
    Friday, October 9, 2026 In today's episode, Dr. Will Flanary (@drglaucomflecken) & Adam Rose (@adjoro) cover Phase 3 results for retatrutide with up to 28.3% average weight loss at 80 weeks. They explain dosing, tolerability and what remains unproven for heart and kidney outcomes and how retatrutide compares with current GLP-1 options. They also break down a federal proposal to modernize airline emergency kits around nine life threatening categories with airline level discretion. Plus: they discuss a growing pediatric heart valve, the return of Doc, Best Medicine, Chicago Med and Grey’s Anatomy, and more. Coverage Timeline: (00:00) Intro (00:50) Retatrutide Weight Loss Trial (03:27) FAA Airline Medical Kits (06:56) Growing Heart Valve (07:26) Fasting Before Blood Work (08:18) Medical Drama Premieres Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit https://www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: https://www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    12 mins
  • The Future of Cancer Screening and... Horse Therapy?

    The Future of Cancer Screening and... Horse Therapy?
    Oct 2 2026
    Friday, October 2, 2026 In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) joins Medlines as a new anchor! She and Eva Johnson cover an FDA advisory panel vote on an early cancer detection blood test for adults 50 and older. The panel called the test safe, then split on whether it works. The agency still has to rule. They also walk through a UCSF comparison of myomectomy and radiofrequency ablation for uterine fibroids. Both treatments improved symptoms over two years, and neither difference reached the study threshold for a clinically important advantage. Plus: new findings on animal therapy, and more. Coverage Timeline: (00:00) Intro (02:01) FDA Backs Multi-Cancer Blood Test (05:08) Uterine Fibroids: Surgery vs. Heat Therapy (07:47) Gambling ER Visits Surge (09:01) Miniature Horses Lift Teen Mood Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    13 mins
  • Life with AI Scribes and Elizabeth Holmes Explained

    Life with AI Scribes and Elizabeth Holmes Explained
    Sep 25 2026
    Friday, September 25, 2026 In today's episode, Dr. Will Flanary (@drglaucomflecken) & Adam Rose (@Adjoro) cover new research on colonoscopy surveillance after high risk adenomas. A large randomized trial found that waiting five years instead of three led to nearly identical colorectal cancer rates. They explain what the interim results mean for screening guidance and what remains unanswered. Then they turn to a Washington court ruling on whether raw audio from an AI scribe counts as part of the medical record. Plus: they discuss Nathan Fielder’s documentary on Theranos founder Elizabeth Holmes, prenatal diet and food allergy risk, and more. Coverage Timeline: (0:00) Intro (0:54) Colonoscopy Intervals (3:55) AI Scribe Ruling (7:25) Theranos Doc (9:07) Conjoined Twins Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    13 mins